The Australasian Psoriasis Collaboration view on methotrexate for psoriasis in the Australasian setting
- 12 July 2016
- journal article
- review article
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 58 (3) , 166-170
Abstract
The Australasian Psoriasis Collaboration reviewed methotrexate (MTX) in the management of psoriasis in the Australian and New Zealand setting. The following comments are based on expert opinion and a literature review. Low‐dose MTX (< 0.4 mg/kg per week) has a slow onset of action and has moderate to good efficacy, together with an acceptable safety profile. The mechanism of action is anti‐inflammatory, rather than immunosuppressive. For pretreatment, consider testing full blood count (FBC), liver and renal function, non‐fasting lipids, hepatitis serology, HbA1c and glucose. Body mass index and abdominal circumference should also be measured. Optional investigations in at‐risk groups include an HIV test, a QuantiFERON‐TB Gold test and a chest X‐ray. In patients without complications, repeat the FBC at 2–4 weeks, then every 3–6 months and the liver/renal function test at 3 months and then every 6 months. There is little evidence that a MTX test dose is of value. Low‐dose MTX rarely causes clinically significant hepatotoxicity in psoriasis. Most treatment‐emergent liver toxicity is related to underlying metabolic syndrome and non‐alcoholic fatty liver disease or non‐alcoholic steatohepatitis. Alcohol itself is not contraindicated, but should be limited to < 20 gm/day. [Correction added on 6 January 2017, after first online publication: ‘20 mg/day’ has been corrected to ‘20 gm/day’.] Although MTX is a potential teratogen post‐conception, there is little evidence for this pre‐conception. MTX does not affect the quality of sperm. There is no evidence that MTX reduces healing, so there is no specific need to stop MTX peri‐surgery. MTX may be used in combination with cyclosporine, acitretin, prednisone and anti‐tumour necrosis factor biologics.Keywords
This publication has 18 references indexed in Scilit:
- Adherence of self‐administered subcutaneous methotrexate in patients with chronic plaque‐type psoriasisJournal of the European Academy of Dermatology and Venereology, 2015
- Methotrexate use and risk of lung disease in psoriasis, psoriatic arthritis, and inflammatory bowel disease: systematic literature review and meta-analysis of randomised controlled trialsBMJ, 2015
- Risk of non‐alcoholic fatty liver disease in patients with psoriasis: a systematic review and meta‐analysisJournal of the European Academy of Dermatology and Venereology, 2014
- A review of methotrexate‐associated hepatotoxicityJournal of Digestive Diseases, 2014
- Methotrexate polyglutamates as a marker of patient compliance and clinical response in psoriasis: a single-centre prospective studyBritish Journal of Dermatology, 2012
- Methotrexate in psoriasis: a systematic review of treatment modalities, incidence, risk factors and monitoring of liver toxicityJournal of the European Academy of Dermatology and Venereology, 2011
- Evidence‐based recommendations on conventional systemic treatments in psoriasis: systematic review and expert opinion of a panel of dermatologistsJournal of the European Academy of Dermatology and Venereology, 2011
- Assessment and management of methotrexate hepatotoxicity in psoriasis patients: report from a consensus conference to evaluate current practice and identify key questions toward optimizing methotrexate use in the clinicJournal of the European Academy of Dermatology and Venereology, 2010
- Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus ConferenceJournal of the American Academy of Dermatology, 2009
- Systemic therapies for psoriasis: methotrexate, retinoids, and cyclosporineClinics in Dermatology, 2008